Read on Twitter
FYI on the #COVID19 #RussianVaccine - tested in an open label, non-randomized phase 1+2 (no placebo) in 38 people combined. Safety monitoring for 2 mo only. cannot even detect common adverse events you might see in 1 in 40 people 
let alone long term or more rare safety issues.
let alone long term or more rare safety issues.
Efficacy endpoint is solely the development of antibodies BUT the researchers did not test for whether those antibodies effectively protect from infection (those two are likely related but not confirmed until ... confirmed).
The only thing newsworthy about this vax is how outrageous it is to grant it approval for wide administration to the public at this stage.
A detailed review on where FDA review process is standing on other vaccines in development is here http://www.fdalawblog.net/2020/08/operation-warp-speed-and-the-standard-for-review-of-the-covid-19-vaccines/
